Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care.

Trento M, Kucich C, Tibaldi P, Gennari S, Tedesco S, Balbo M, Arvat E, Cavallo F, Ghigo E, Porta M.

J Endocrinol Invest. 2010 Oct;33(9):624-8. doi: 10.3275/6815. Epub 2010 Feb 5.

PMID:
20142635
2.

Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.

Berardelli R, Margarito E, Ghiggia F, Picu A, Balbo M, Bonelli L, Giordano R, Karamouzis I, Bo M, Ghigo E, Arvat E.

J Endocrinol Invest. 2010 Oct;33(9):657-62. doi: 10.3275/6994. Epub 2010 Apr 22.

3.

Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.

Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M.

Eur J Pain. 2005 Feb;9(1):33-8.

PMID:
15629872
4.

Neuroendocrine effects of citalopram infusion in anorexia nervosa.

Mondelli V, Gianotti L, Picu A, Abbate Daga G, Giordano R, Berardelli R, Pariante CM, Fassino S, Ghigo E, Arvat E.

Psychoneuroendocrinology. 2006 Nov;31(10):1139-48. Epub 2006 Oct 11.

PMID:
17045409
5.

Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study.

Ljung T, Ahlberg AC, Holm G, Friberg P, Andersson B, Eriksson E, Björntorp P.

J Intern Med. 2001 Sep;250(3):219-24.

7.

Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.

Nikisch G, Mathé AA, Czernik A, Thiele J, Bohner J, Eap CB, Agren H, Baumann P.

Psychopharmacology (Berl). 2005 Oct;181(4):751-60. Epub 2005 Sep 29.

PMID:
15988572
8.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
9.

Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats.

Jensen JB, Jessop DS, Harbuz MS, Mørk A, Sánchez C, Mikkelsen JD.

J Neuroendocrinol. 1999 Jun;11(6):465-71.

PMID:
10336728
10.

Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.

Jiang T, Rong Z, Xu Y, Chen B, Xie Y, Chen C, Lu Y, Shen Y, Li H, Sun J, Chen H.

Clin Drug Investig. 2013 Jan;33(1):1-9. doi: 10.1007/s40261-012-0010-8.

PMID:
23179471
11.

Citalopram, escitalopram, and the QT interval.

[No authors listed]

Med Lett Drugs Ther. 2013 Jul 22;55(1421):59. No abstract available.

PMID:
23863918
12.

Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women.

Laferrère B, Lahlou N, Saltiel H, Roger M, Basdevant A, Oppert JM, Guy-Grand B.

Obes Res. 1994 Jul;2(4):328-36.

13.

Relationship between type 2 diabetes mellitus and hypothalamic-pituitary-adrenal axis.

Felšöci M, Schroner Z, Petrovičová J, Lazúrová I.

Wien Klin Wochenschr. 2011 Jan;123(1-2):28-33. doi: 10.1007/s00508-010-1497-8. Epub 2010 Dec 20.

PMID:
21165705
14.

Studies on the neuroendocrine role of serotonin.

Jørgensen HS.

Dan Med Bull. 2007 Nov;54(4):266-88. Review.

PMID:
18208678
15.

Escitalopram prolonged fear induced by simulated public speaking and released hypothalamic-pituitary-adrenal axis activation.

Garcia-Leal C, Del-Ben CM, Leal FM, Graeff FG, Guimarães FS.

J Psychopharmacol. 2010 May;24(5):683-94. doi: 10.1177/0269881108101782. Epub 2009 Feb 27.

PMID:
19251828
16.

Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.

Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG.

Psychopharmacology (Berl). 2005 Mar;178(2-3):268-75. Epub 2004 Sep 9.

PMID:
15365685
17.
19.

The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls.

Kilkens TO, Honig A, Fekkes D, Brummer RJ.

Aliment Pharmacol Ther. 2005 Nov 1;22(9):865-74.

20.

Citalopram neuropharmacological challenge in alcohol-dependent patients and controls: pharmacogenetic, endocrine and psychobehavioral results.

Wong WM, Hasemann S, Schwarz M, Zill P, Koller G, Soyka M, Preuss UW.

Pharmacopsychiatry. 2008 Mar;41(2):72-8. doi: 10.1055/s-2007-1004595.

PMID:
18311688

Supplemental Content

Support Center